Detail

Keywords

Neurooncology; Pediatrics

Research group(s)

• Pediatric Neuro-Oncology
  Research Area: - Precision oncology for pediatric CNS tumors - Development of innovative tumor models for pediatric CNS tumors - Identification of novel targets and therapies for pediatric CNS tumors - Discovery and translational application of biomarkers with focus on liquid biopsy
  Members:
  Johannes Gojo
  Cora Hedrich
  Andreas Peyrl
  Hannah Schned

Research interests

In the Pediatric Neuro-Oncology program at the Medical University of Vienna we serve pediatric, adolescent, and young adult patients with central nervous system tumors. In collaboration with neurosurgery, neuropathology, radiation oncology, neuropsychology and basic science colleagues we provide comprehensive multi-disciplinary care. We offer innovative clinical trials and industry-sponsored initiatives.

The interest of my research is focused on pediatric brain tumors, especially in the recurrent situation. The primary research interest is the identification of drivers of the disease, mainly in the CSF, and particular targeted on medulloblastoma and the identification of biological factors that lead to recurrence. The basic and translational research is focused on the microenvironment of tumors, especially the CSF, with the key aspects of antiangiogenic therapy and intraventricular therapy.

The clinical research centers on the development of new (targeted) therapies for children with brain tumors. I serve as the lead investigator of the MEMMAT trial (Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial), an academic phase II study for patients with recurrent or progressive medulloblastoma (ClinicalTrials.gov_Identifier: NCT01356290). I have served as institutional Principal Investigator for clinical trials derived with industry partners and have developed expertise in safety monitoring on clinical trials by serving on Data Safety Monitoring Boards. 

Selected publications

1. Peyrl, A. et al. (2023) ‘Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen’, JAMA Oncology, 9(12), p. 1688. Available at: https://doi.org/10.1001/jamaoncol.2023.4437.
2. Reichl, B. et al. (2020) ‘Determination of a Tumor-Promoting Microenvironment in Recurrent Medulloblastoma: A Multi-Omics Study of Cerebrospinal Fluid’, Cancers, 12(6), p. 1350. Available at: https://doi.org/10.3390/cancers12061350.
3. Hovestadt, V. et al. (2019) ‘Resolving medulloblastoma cellular architecture by single-cell genomics’, Nature, 572(7767), pp. 74–79. Available at: https://doi.org/10.1038/s41586-019-1434-6.
4. Filbin, M.G. et al. (2018) ‘Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq’, Science, 360(6386), pp. 331–335. Available at: https://doi.org/10.1126/science.aao4750.
5. Peyrl, A. et al. (2014) ‘Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients’, Journal of Neuro-Oncology, 120(1), pp. 139–145. Available at: https://doi.org/10.1007/s11060-014-1531-1.